← Skin Intelligence Digest
Emergingingredients

Niacinamide Is Suddenly in Everything, Everywhere. But Is It Too Much of a Good Thing?

Published June 10, 20261 min read
Intelligence brief

When news of Armani’s reformulated Luminous Silk foundation dropped late last year, beauty fans took to Instagram comments to share their excitement, curiosity, and disappointment—mostly in the brand’s choice to include the popular skincare ingredient niacinamide. “Ugh, my skin hates niacinamide,” wrote one user, while another added: “Please not more niacinamide.” “Although niacinamide is often marketed as a gentle ingredient, I have seen patients develop irritation from it,” says Mona Foad , a board-certified dermatologist and founder of MONA Dermatology . “It's not because niacinamide is inherently harsh, but usually because consumers are layering multiple products containing the ingredient or choosing formulations with intense, high concentrations. As niacinamide has become more common, people may unknowingly be layering it several times throughout their routine, and this is what can increase the risk of redness, stinging, or irritation, especially in sensitive skin types.” “I don't think niacinamide is a passing trend. It has a strong amount of research behind it and offers real benefits for many patients,” says Foad. “However, not every product needs to contain it. I would rather see patients use a few well-formulated products consistently than feel pressured to chase a single ingredient in every step of their routine.”

Key signals
  • Ingredient signal
    Coverage centres on niacinamide, pay attention to concentration, vehicle, and pairings in your routine before changing anything material.
Ingredients referenced
Related research in the vault
ingredientsRCT

Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration.

J Peripher Nerv Syst · Mar 2026

Recent preclinical studies have shown that nicotinamide adenine dinucleotide (NAD+) plays a critical role in molecular mechanisms of axon degeneration, and reductions in NAD+ levels are associated with axonal degeneration. Nicotinamide riboside (NR) is a safe and widely available pyridine-nucleoside form of vitamin B3 and is an NAD+ precursor. To investigate if oral supplementation of synthetic NR can act as a therapeutic agent to prevent degeneration of small somatic sensory axons innervating the skin or promote regeneration of these same fibers in humans, we utilized a validated experimental model of cutaneous nerve degeneration and regeneration and conducted a placebo-controlled, double-blinded Phase 2 study.

niacinamidepharct
Read →
ingredientsRCT

Changes in ultraviolet a radiation-induced thymidine dimers and erythema after oral nicotinamide or polypodium leucotomos extract in healthy volunteers: a randomized intraindividual trial.

Photochem Photobiol Sci · May 2026

Nicotinamide (NAM) and Polypodium leucotomos extract (PL) have demonstrated photoprotective effects, but their role in preventing UVA-induced DNA damage in humans remains unclear. To evaluate the effects of oral NAM and PL on UVA-induced erythema and thymidine dimer (TT-dimer) formation. In this intraindividual trial, 50 healthy volunteers (phototypes I-III) were randomized (1:1) to receive either NAM (2000 mg daily) or PL (Heliocare Advanced: 480 mg daily) for 30 days.

niacinamidepharosacea
Read →
ingredientsRCT

Safety and efficacy of individualised exercise and NAD(+) precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial.

Lancet Neurol · May 2026

Friedreich's ataxia is a rare, chronic, progressive, neurodegenerative condition affecting multiple organ systems, including neurological, musculoskeletal, cardiac, and endocrine systems, and is marked by low cardiopulmonary fitness. We tested the effect of exercise and NAD+ precursor supplementation with nicotinamide riboside, which have each shown benefits in animal and early clinical studies, on cardiopulmonary fitness in individuals with Friedreich's ataxia. This 12-week, outpatient, phase 2, single-site (Children's Hospital of Philadelphia, Philadelphia, PA, USA), randomised, 2 × 2 factorial clinical trial recruited individuals aged 10-40 years with an ejection fraction of 45% or greater who were able to exercise.

niacinamidepharct
Read →

This intelligence brief synthesizes reporting from beauty and dermatology industry publications.

View source →

This information is for educational purposes only and is not medical advice. Individual results vary. Consult a qualified dermatologist or healthcare professional for medical concerns. Full disclaimer →